Production (Stage)
Mydecine Innovations Group Inc.
MYCO
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 258.70K | 449.90K | 360.10K | 551.10K | 453.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 258.70K | -1.45M | 1.20M | 1.65M | 463.10K |
| Operating Income | -258.70K | 1.45M | -1.20M | -1.65M | -463.10K |
| Income Before Tax | -208.20K | 1.80M | -1.46M | -1.95M | -753.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -208.20K | 1.80M | -1.46M | -1.95M | -753.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.20K | 1.80M | -1.46M | -1.95M | -753.40K |
| EBIT | -258.70K | 1.45M | -1.20M | -1.65M | -463.10K |
| EBITDA | -- | 1.45M | -1.20M | -1.65M | -461.20K |
| EPS Basic | 0.00 | 0.03 | -0.02 | -0.03 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.01 | -0.01 | -0.02 | -0.01 |
| EPS Diluted | 0.00 | 0.03 | -0.02 | -0.03 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.01 | -0.01 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 61.76M | 61.63M | 61.76M | 61.19M | 53.80M |
| Average Diluted Shares Outstanding | 61.76M | 61.63M | 61.76M | 61.19M | 53.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |